HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on OKYO Pharma, maintaining a price target of $7. This suggests confidence in the company's future performance.
August 27, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on OKYO Pharma, maintaining a price target of $7. This indicates a positive outlook from the analyst.
The reiteration of a Buy rating and maintenance of a $7 price target by HC Wainwright & Co. suggests confidence in OKYO Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100